Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing
Reexamination Certificate
2002-07-05
2010-06-08
Canella, Karen A (Department: 1643)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
C424S093210, C424S093710, C435S375000, C435S377000, C435S386000
Reexamination Certificate
active
07731950
ABSTRACT:
This invention is directed to therapeutic compositions containing non-MHC-restricted T-cells/NK-cells in combination with MHC-restricted T-cells and especially to therapeutic compositions, which comprise LAK cells. Furthermore, the present invention is directed to the use of the above combination in the treatment of tumors in humans, which tumors show a missing, low or aberrant expression of MHC class 1a or 1b molecules. By using the aforementioned compositions/combinations it is possible to provide a balanced selective pressure against emergence of tumor cell variants that would otherwise escape immune detection.
REFERENCES:
patent: 5229115 (1993-07-01), Lynch
patent: 6261839 (2001-07-01), Multhoff et al.
patent: 6849452 (2005-02-01), Zitvogel et al.
patent: 2001/0012632 (2001-08-01), Moser et al.
patent: 2002/0177551 (2002-11-01), Terman
patent: 2 775 692 (1999-09-01), None
patent: WO 97/29182 (1997-08-01), None
patent: WO 98/48630 (1998-11-01), None
Stedman's Medical Dictionary, (on-line version) 2000, lines 1-3).
Abstract of Wheeler (Salud p'ublica de M'exico, Jul.-Aug. 1997, vol. 39, No. 4, pp. 283-287).
Efferson et al (Anticancer research, 2005, vol. 25, pp. 715-724).
Bachman et al (Journal of Immunology, 2005, vol. 175, pp. 4677-4685).
Kale et al (European Journal of Immunology, 1990, vol. 20, pp. 369-377).
Schendel et al (Cancer Research, 1993, vol. 53, pp. 4020-4025).
Finke et al (Immunology Today, Apr. 1999, vol. 20, pp. 158-160).
Abstract of Uberti et al (Clinical Immunology and Immunopathology, 1994, vol. 70, pp. 234-240).
Yamamoto et al (Clin Exp Immunol, 1995, vol. 100, pp. 13-20).
Cesano et al (Journal of Clinical Investigation, 1994, vol. 94, pp. 1076-1084).
Cruse et al., “Immunol Immunophermacol,” Lifesci 89, vol. 9 ( No. 2), p. 41-53, (1989).
Baxeranis et al., “Lancer Immunology, Immunotherapy,” Medline, vol. 40 ( No. 6), p. 410-8, (1995).
Schlebusch et al., “Hybridoma,” Medline, vol. 14 ( No. 2), p. 167-74, (1995).
Melief et al., “Res. Immunol,” Medline, vol. 142 ( No. 5-6), p. 425-9, (1991).
G.P. Leong, “Surgical Clinics of North America,” Medline, vol. 76 ( No. 6), p. 1355-81, (1996).
Schendel et al., “Mol. Med.,” Medline, vol. 75 ( No. 6), p. 400-13, (1997).
Abe et al., “Lymphotcine Cytokine Res.,” Medline, vol. 12 ( No. 5), p. 279-83, (1993).
Giorgio Parmiani, “An explanation of the variable clinical response to interleukin 2 and LAK cells,” Immunology Today, Elsevier Science Publishers Ltd. (UK), vol. 11 ( No. 04), p. 113-115, (1990).
Hoffman et al., “Adoptive Cellular Therapy,” Seminars in Oncology, vol. 27 ( No. 02), p. 221-233, (Apr. 2000).
Falk Christine
Noessner Elfriede
Schendel Dolores
Weiss Elisabeth
Canella Karen A
Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesund
Jenkins Wilson Taylor & Hunt, P.A.
LandOfFree
Attack of tumor cells with missing, low or aberrant MHC... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Attack of tumor cells with missing, low or aberrant MHC..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Attack of tumor cells with missing, low or aberrant MHC... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4201697